Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Перименопауза: от контрацепции к заместительной гормональной терапии. Преимущества дроспиренона (В помощь практикующему врачу)
Перименопауза: от контрацепции к заместительной гормональной терапии. Преимущества дроспиренона (В помощь практикующему врачу)
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ 2007; 335: 651.
2. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer 2006; 95: 385–9.
3. Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303–14.
4. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577–82.
5. Scouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004; 9: 57–68.
6. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996; 61: 166–71.
7. Rosano GM, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric 2006; 9 (Suppl. 1): 19–27.
8. Perchere-Betschi A, Bunier M. Female sex hormones, salt and blood pressure regulation. Am J Hypertens 2004; 17: 994–1001.
9. Hernandez Schulman I, Aranda P, Raij L. Surgical menopause increases salt sensitivity of blood pressure. Hypertension 2006; 47: 1168–74.
10. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345 (18): 1291–7.
11. Oelkers W, Foidart JM, Dombrovicz N et al. Effects of a new oral contraceptive containing an antimineralocorticoid proges-togen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–21.
12. Прилепская В.Н. Руководство по контрацепции. М., 2006.
13. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies Gynecological Endocrinology 2007; 23 (3): 123–30.
14. Angst J, Sellaro R, Stolar M et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001; 104: 110–6.
15. Borenstein JE, Dean BB, Endicott J et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003; 48: 515–24.
16. Chawla A, Swindle R, Long S et al. Premenstrual dysphoric disorder: is there an economic burden of illness? Med Care 2002; 40: 1101–12.
17. Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder – clinical procedures and research perspectives. Gyn Endocrinol 2004; 19: 320–34.
18. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002; 32: 119–32.
19. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Women Ment Health 2006; 9: 41–9.
20. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414–21.
21. Maloney JM, Kunz M, Lee-Rugh S et al. Drospirenone 3 mg/ethinylestradiol 20 mcg combined oral contraceptive in the treatment of acne vulgaris: lesion count, ISGA. Obstet Gynecol 2007; 109: 11S.
22. Koltun W, Lucky AW, Thiboutot D et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249–56.
23. Gray RH. Biological and social interactions in determination of late fertility. J Biosoc Sci 1979; Suppl. 6: 97–115.
24. Archer DF, Thorneycroft IH, Foegh M et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716–27.
25. White WB, Pitt B, Preston RA, Hanes V. Effect of a New Hormone therapy, DRSP and 17 b-E2 in Postmenopausal Women with Hypertension. Hypertension 2006; 48: 1–8.
26. Прилепская В.Н. Новые возможности и перспективы современной контрацепции. Пробл. репродукции. 2009; 5: 59–61.
27. Knuuiti J, Kallokoski R, Janatuinen T et al. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. Am J Cardiol 2007; 99: 1648–52.
28. Carpio M, Zennaro M-C, Feve B et al. Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with mineralocorticoid receptor. Climacteric 2008; 11: 258–64.
29. Tanko LB, Christiansen C. Effects of 17 b-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Internal Med 2005; 258: 544–53.
30. Порывкина О.Н., Адашева Т.В., Задионченко В.С. и др. Эффективность и безопасность применения препарата Анжелик у пациенток с метаболическим синдромом в постменопаузе. 2008.
2. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer 2006; 95: 385–9.
3. Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303–14.
4. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577–82.
5. Scouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004; 9: 57–68.
6. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996; 61: 166–71.
7. Rosano GM, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric 2006; 9 (Suppl. 1): 19–27.
8. Perchere-Betschi A, Bunier M. Female sex hormones, salt and blood pressure regulation. Am J Hypertens 2004; 17: 994–1001.
9. Hernandez Schulman I, Aranda P, Raij L. Surgical menopause increases salt sensitivity of blood pressure. Hypertension 2006; 47: 1168–74.
10. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345 (18): 1291–7.
11. Oelkers W, Foidart JM, Dombrovicz N et al. Effects of a new oral contraceptive containing an antimineralocorticoid proges-togen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–21.
12. Прилепская В.Н. Руководство по контрацепции. М., 2006.
13. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies Gynecological Endocrinology 2007; 23 (3): 123–30.
14. Angst J, Sellaro R, Stolar M et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001; 104: 110–6.
15. Borenstein JE, Dean BB, Endicott J et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003; 48: 515–24.
16. Chawla A, Swindle R, Long S et al. Premenstrual dysphoric disorder: is there an economic burden of illness? Med Care 2002; 40: 1101–12.
17. Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder – clinical procedures and research perspectives. Gyn Endocrinol 2004; 19: 320–34.
18. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002; 32: 119–32.
19. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Women Ment Health 2006; 9: 41–9.
20. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414–21.
21. Maloney JM, Kunz M, Lee-Rugh S et al. Drospirenone 3 mg/ethinylestradiol 20 mcg combined oral contraceptive in the treatment of acne vulgaris: lesion count, ISGA. Obstet Gynecol 2007; 109: 11S.
22. Koltun W, Lucky AW, Thiboutot D et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249–56.
23. Gray RH. Biological and social interactions in determination of late fertility. J Biosoc Sci 1979; Suppl. 6: 97–115.
24. Archer DF, Thorneycroft IH, Foegh M et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716–27.
25. White WB, Pitt B, Preston RA, Hanes V. Effect of a New Hormone therapy, DRSP and 17 b-E2 in Postmenopausal Women with Hypertension. Hypertension 2006; 48: 1–8.
26. Прилепская В.Н. Новые возможности и перспективы современной контрацепции. Пробл. репродукции. 2009; 5: 59–61.
27. Knuuiti J, Kallokoski R, Janatuinen T et al. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. Am J Cardiol 2007; 99: 1648–52.
28. Carpio M, Zennaro M-C, Feve B et al. Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with mineralocorticoid receptor. Climacteric 2008; 11: 258–64.
29. Tanko LB, Christiansen C. Effects of 17 b-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Internal Med 2005; 258: 544–53.
30. Порывкина О.Н., Адашева Т.В., Задионченко В.С. и др. Эффективность и безопасность применения препарата Анжелик у пациенток с метаболическим синдромом в постменопаузе. 2008.
2. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer 2006; 95: 385–9.
3. Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303–14.
4. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577–82.
5. Scouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004; 9: 57–68.
6. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996; 61: 166–71.
7. Rosano GM, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric 2006; 9 (Suppl. 1): 19–27.
8. Perchere-Betschi A, Bunier M. Female sex hormones, salt and blood pressure regulation. Am J Hypertens 2004; 17: 994–1001.
9. Hernandez Schulman I, Aranda P, Raij L. Surgical menopause increases salt sensitivity of blood pressure. Hypertension 2006; 47: 1168–74.
10. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345 (18): 1291–7.
11. Oelkers W, Foidart JM, Dombrovicz N et al. Effects of a new oral contraceptive containing an antimineralocorticoid proges-togen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–21.
12. Прилепская В.Н. Руководство по контрацепции. М., 2006.
13. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies Gynecological Endocrinology 2007; 23 (3): 123–30.
14. Angst J, Sellaro R, Stolar M et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001; 104: 110–6.
15. Borenstein JE, Dean BB, Endicott J et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003; 48: 515–24.
16. Chawla A, Swindle R, Long S et al. Premenstrual dysphoric disorder: is there an economic burden of illness? Med Care 2002; 40: 1101–12.
17. Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder – clinical procedures and research perspectives. Gyn Endocrinol 2004; 19: 320–34.
18. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002; 32: 119–32.
19. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Women Ment Health 2006; 9: 41–9.
20. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414–21.
21. Maloney JM, Kunz M, Lee-Rugh S et al. Drospirenone 3 mg/ethinylestradiol 20 mcg combined oral contraceptive in the treatment of acne vulgaris: lesion count, ISGA. Obstet Gynecol 2007; 109: 11S.
22. Koltun W, Lucky AW, Thiboutot D et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249–56.
23. Gray RH. Biological and social interactions in determination of late fertility. J Biosoc Sci 1979; Suppl. 6: 97–115.
24. Archer DF, Thorneycroft IH, Foegh M et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716–27.
25. White WB, Pitt B, Preston RA, Hanes V. Effect of a New Hormone therapy, DRSP and 17 b-E2 in Postmenopausal Women with Hypertension. Hypertension 2006; 48: 1–8.
26. Прилепская В.Н. Новые возможности и перспективы современной контрацепции. Пробл. репродукции. 2009; 5: 59–61.
27. Knuuiti J, Kallokoski R, Janatuinen T et al. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. Am J Cardiol 2007; 99: 1648–52.
28. Carpio M, Zennaro M-C, Feve B et al. Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with mineralocorticoid receptor. Climacteric 2008; 11: 258–64.
29. Tanko LB, Christiansen C. Effects of 17 b-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Internal Med 2005; 258: 544–53.
30. Порывкина О.Н., Адашева Т.В., Задионченко В.С. и др. Эффективность и безопасность применения препарата Анжелик у пациенток с метаболическим синдромом в постменопаузе. 2008.
________________________________________________
2. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer 2006; 95: 385–9.
3. Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303–14.
4. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577–82.
5. Scouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004; 9: 57–68.
6. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996; 61: 166–71.
7. Rosano GM, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric 2006; 9 (Suppl. 1): 19–27.
8. Perchere-Betschi A, Bunier M. Female sex hormones, salt and blood pressure regulation. Am J Hypertens 2004; 17: 994–1001.
9. Hernandez Schulman I, Aranda P, Raij L. Surgical menopause increases salt sensitivity of blood pressure. Hypertension 2006; 47: 1168–74.
10. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345 (18): 1291–7.
11. Oelkers W, Foidart JM, Dombrovicz N et al. Effects of a new oral contraceptive containing an antimineralocorticoid proges-togen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–21.
12. Прилепская В.Н. Руководство по контрацепции. М., 2006.
13. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies Gynecological Endocrinology 2007; 23 (3): 123–30.
14. Angst J, Sellaro R, Stolar M et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001; 104: 110–6.
15. Borenstein JE, Dean BB, Endicott J et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003; 48: 515–24.
16. Chawla A, Swindle R, Long S et al. Premenstrual dysphoric disorder: is there an economic burden of illness? Med Care 2002; 40: 1101–12.
17. Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder – clinical procedures and research perspectives. Gyn Endocrinol 2004; 19: 320–34.
18. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002; 32: 119–32.
19. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Women Ment Health 2006; 9: 41–9.
20. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414–21.
21. Maloney JM, Kunz M, Lee-Rugh S et al. Drospirenone 3 mg/ethinylestradiol 20 mcg combined oral contraceptive in the treatment of acne vulgaris: lesion count, ISGA. Obstet Gynecol 2007; 109: 11S.
22. Koltun W, Lucky AW, Thiboutot D et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249–56.
23. Gray RH. Biological and social interactions in determination of late fertility. J Biosoc Sci 1979; Suppl. 6: 97–115.
24. Archer DF, Thorneycroft IH, Foegh M et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716–27.
25. White WB, Pitt B, Preston RA, Hanes V. Effect of a New Hormone therapy, DRSP and 17 b-E2 in Postmenopausal Women with Hypertension. Hypertension 2006; 48: 1–8.
26. Прилепская В.Н. Новые возможности и перспективы современной контрацепции. Пробл. репродукции. 2009; 5: 59–61.
27. Knuuiti J, Kallokoski R, Janatuinen T et al. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. Am J Cardiol 2007; 99: 1648–52.
28. Carpio M, Zennaro M-C, Feve B et al. Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with mineralocorticoid receptor. Climacteric 2008; 11: 258–64.
29. Tanko LB, Christiansen C. Effects of 17 b-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Internal Med 2005; 258: 544–53.
30. Порывкина О.Н., Адашева Т.В., Задионченко В.С. и др. Эффективность и безопасность применения препарата Анжелик у пациенток с метаболическим синдромом в постменопаузе. 2008.
Авторы
В.Н.Прилепская, В.П.Сметник
ФГУ Научноый центр акушерства, гинекологии и перинатологии Росмедтехнологий им. В.И. Кулакова
(дир. – Акад. РАМН, д.м.н., проф. Г.Т. Сухих), Москва
ФГУ Научноый центр акушерства, гинекологии и перинатологии Росмедтехнологий им. В.И. Кулакова
(дир. – Акад. РАМН, д.м.н., проф. Г.Т. Сухих), Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.